We are live on ! Find out more
SGMT icon

Sagimet Biosciences

70 hedge funds and large institutions have $44.9M invested in Sagimet Biosciences in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

24% more call options, than puts

Call options by funds: $539K | Put options by funds: $436K

6% more funds holding

Funds holding: 6670 (+4)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

11% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 18

12.14% less ownership

Funds ownership: 57.04%44.9% (-12%)

43% less capital invested

Capital invested by funds: $78.8M → $44.9M (-$33.8M)

Holders
70
Holders Change
+4
Holders Change %
+6.06%
% of All Funds
0.94%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
16
Reduced
18
Closed
13
Calls
$539K
Puts
$436K
Net Calls
+$103K
Net Calls Change
+$1.09M
Name Holding Trade Value Shares
Change
Change in
Stake
EGM
76
Engineers Gate Manager
New York
-$150K -33,351 Closed
VF
77
Virtu Financial
New York
-$113K -25,043 Closed
OWP
78
ORG Wealth Partners
Texas
-$96.5K -21,448 Closed
SC
79
Shay Capital
New York
-$87K -19,332 Closed
Man Group
80
Man Group
United Kingdom
-$77.9K -17,322 Closed
Simplex Trading
81
Simplex Trading
Illinois
-$71.9K -17,147 Closed
Renaissance Technologies
82
Renaissance Technologies
New York
-$48.6K -10,800 Closed
AAP
83
Arax Advisory Partners
Colorado
-$518 -115 Closed

SGMT Hedge Fund Activity: Q1 2025 in Review

70 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q1 2025, worth a combined $44.9M — down 43% from $78.8M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new SGMT positions and 13 closed out — a net gain of 5 holders — while 16 added to existing stakes and 18 trimmed.

The largest buyer was Raymond James Financial, opening a new position worth an estimated $1.45M. The largest seller was NEA Management Company, exiting entirely with an estimated $9M sold.

  • 70 institutional investors held Sagimet Biosciences (SGMT) as of Q1 2025, up from 66 in Q4 2024.
  • Funds reported $44.9M of Sagimet Biosciences stock for Q1 2025, down 43% quarter-over-quarter.
  • 18 funds opened new Sagimet Biosciences positions in Q1 2025 and 13 closed out, a net change of +5 holders.
  • The largest Sagimet Biosciences buyer in Q1 2025 was Raymond James Financial, an estimated $1.45M added.
  • The largest Sagimet Biosciences seller in Q1 2025 was NEA Management Company, an estimated $9M sold.

Based on aggregated 13F filings for Q1 2025.